Takeda Confirms Long-Term Protection And Safety Of QDENGA Dengue Vaccine

Takeda (TSE:4502/NYSE:TAK) announced the successful completion of its seven-year Phase 3 TIDES trial, confirming the long-term efficacy and safety of its dengue vaccine, QDENGA® (TAK-003). Results showed that the two-dose regimen provided sustained protection against all four dengue virus serotypes, with a 61.2% efficacy against virologically confirmed dengue after 4.5 years and 84.1% efficacy in preventing hospitalizations. An exploratory booster dose slightly improved efficacy to 74.3% after two years, maintaining a strong safety profile without new adverse signals.

Experts highlighted the vaccine’s importance amid a global dengue surge, particularly in regions like Brazil, which has faced record-high cases driven by climate change and rapid urbanization. According to the Oswaldo Cruz Foundation, the inclusion of QDENGA in Brazil’s national immunization program has already reduced symptomatic dengue cases and hospitalizations, reinforcing its public health impact.

Takeda emphasized that QDENGA is now one of the most comprehensively studied dengue vaccines, with over 60,000 participants worldwide and approvals in 41 countries since 2022. With 18.6 million doses distributed across 11 endemic nations, QDENGA has also earned WHO prequalification, validating its quality for global use. Takeda continues to conduct post-marketing research and real-world studies in Latin America and Southeast Asia to monitor long-term effectiveness and safety, supporting the company’s mission toward a dengue-free future.